Malignant hematology pharmacist and affiliate assistant professor @MUSCHollings #lymphoma #myeloma opinions are my own
Charleston, SC
Joined May 2021
- Tweets338
- Following210
- Followers629
- Likes2.1K
James Davis, PharmD, BCOP retweeted
New WolverHeme Happy Hour!!!!🎙️ @Berninini & @ajperissinotti are joined by @thisisJamesD, @drrx4L, @Papa_Heme, Jon Weiss to tackle frontline DLBCL: we critically appraise frontMIND and intertwine POLARIX, and EPCORE-DLBCL2. What’s ready to change practice? open.spotify.com/episode/2zX…
🤖 Made with AI
James Davis, PharmD, BCOP retweeted
Efficacy of Stem Cell Boost (SCB) for CAR-T-related hematologic toxicity in #RRMM-RWE from the US multiple myeloma immunotherapy consortium
rdcu.be/fa4XX
Fortunate to have played a small part in this tremendous effort by #CindyVarga 👏🙌🎆
#MMSM #Medtwitter @BloodCancerJnl
@thisisJamesD @khouri_jack @ForsbergMD @AimazAfrough @ldandersonjr @leshune @TomBmt133 #DorisHansen & many more
James Davis, PharmD, BCOP retweeted
#Myeloma Paper of the Day: Analysis from US Multiple Myeloma Immunotherapy Consortium of real-world elranatamab data finds median PFS & OS 4.3 & 14.6 mos; elevated LDH & low Hgb predict poor outcomes; prior BCMA exposure reduced response depth: pubmed.ncbi.nlm.nih.gov/4189…. #mmsm
James Davis, PharmD, BCOP retweeted
Measles is back. For myeloma patients after ASCT, MMR often gets delayed because of vaccine timing & concern about dara maintenance. This multicenter study provides reassuring safety data & should give clinicians confidence to vaccinate when appropriate. ashpublications.org/bloodneo…
Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time.
"Can I get MMR 💉 on dara-len maintenance?"
Short answer: 💯%, it seems!
Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!
James Davis, PharmD, BCOP retweeted
Great to see in @BloodPortfolio Neoplasia since it's a question our #MMsm patients ask all the time.
"Can I get MMR 💉 on dara-len maintenance?"
Short answer: 💯%, it seems!
Long answer: Kudos to our PharmD colleagues within 🇺🇸 MM Consortium for leading the charge on this!
James Davis, PharmD, BCOP retweeted
#ASH25 Come swing by our poster #4066. We show the incidence, risk factor and outcome of CV events during teclistamab in a multicenter registry! #USMMITC @MoffittNews @PennCardiology @PennCancer @md_addison @RahulBanerjeeMD @thisisJamesD amongst many others!
James Davis, PharmD, BCOP retweeted
#5 Stem cell boost as treatment for cytopenias after CART. Cindy Varga et al. @SurbhiSidanaMD @hhashmi87 @TomBmt133
Highly effective, safe, and practical. #ASH25
Link: meetings-api.hematology.org/…
James Davis, PharmD, BCOP retweeted
Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd – DRAFT Update: 12/1/25 v2 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani @DrOlaLandgren
James Davis, PharmD, BCOP retweeted
For patients with myeloma #MMsm and no response after 1 month of bispecific antibodies, should therapy be continued or changed? More by @RahulBanerjeeMD et al out now in @AjHematology.
doi.org/10.1002/ajh.70108
@AlGarfall
James Davis, PharmD, BCOP retweeted
#Myeloma Paper of the Day: Real-world study of bispecific T-cell engager safety & efficacy in systemic AL #amyloidosis finds heme ORR 76% (66% CR, 7% VGPR), MRD-negative in 6/6 tested, cardiac & renal response in 64% & 100%; CRS in 45% (all G 1/2): pubmed.ncbi.nlm.nih.gov/4122…. #mmsm
James Davis, PharmD, BCOP retweeted
Dex for management of CRS assoc w/ talquetamab [GPRC5D-targeting bispecific antibody (bsAb)] in Pts w/ RRMM [Nov 3, 2025] McElwee et al. #ASH25 abs25-14627 PID 720
submit.hematology.org/progra… #mmsm #SuppOnc
James Davis, PharmD, BCOP retweeted
10/ #ASH25 Abstract 720: 1st-line CRS Tx with dex in #MMsm bsAbs (McElwee @thisisJamesD et al)
"Pocket dex": equal efficacy, way cheaper / simpler than toci, albeit >1 dose more likely.
This makes outpt bsAb SUD *way* easier for pts.
As I now say:
#Downwithdex
#ExceptforCRS !
James Davis, PharmD, BCOP retweeted
Safety of live-attenuated MMR vaccination in Pts w/ multiple myeloma receiving daratumumab after autologous stem cell transplantation (ASCT) [Nov 3, 2025] Davis et al. #ASH25 abs25-1551
meetings-api.hematology.org/…
#mmsm #bmtsm #IDonc #ImmunoOnc
James Davis, PharmD, BCOP retweeted
Designing a strong bridge to CAR-T cells with bispecifics ow.ly/TSpT50Xh8x8 #immunobiologyandimmunotherapy
James Davis, PharmD, BCOP retweeted
1/ Thanks Larry (and all co-authors) and @AjHematology for this!
RW data for a frequent q in my own #MMsm clinic, namely patients starting teclistamab disappointed by D30 results after hearing "Median time to 1st response 1.1 mo"...
Can we predict delayed response conversion?
Great job leading this one @RahulBanerjeeMD D30 ALC is a significant predictor of delayed responses to Tec in RRMM for initial non-responders. American Journal of Hematology | onlinelibrary.wiley.com/doi/… @GKaurMD @AlGarfall @SurbhiSidanaMD @utswcancer #USMyelomaImmunotherapyConsortium
James Davis, PharmD, BCOP retweeted
#Myeloma Paper of the Day: Targeting w/ talquetamab as bridge to BCMA CAR-T shows no grade ≥3 CRS, 2% grade 3 ICANS & grade 1-2 talq unique toxicities, 71% ORR, post CAR-T 88% responded/54% CR, 2 grade ≥3 CRS, 1 grade 3 ICANS, 5% grade ≥3 infxns: pubmed.ncbi.nlm.nih.gov/4074…. #mmsm
James Davis, PharmD, BCOP retweeted
1/ As @End_myeloma has said so eloquently:
"The only place where BCMA must come before GPRC5D is the dictionary."
Talquetamab bridging before BCMA CAR-T in myeloma - short, very effective, and rapidly becoming my preferred approach for patients with aggressive #MMsm biology!
🎉Finally out🎉
Talquetamab bridging is feasible, safe and effective allowing rapid disease control with minimal grade toxicity
@BloodPortfolio
ashpublications.org/blood/ar…
#mmsm
James Davis, PharmD, BCOP retweeted
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma | Blood Cancer Journal nature.com/articles/s41408-0…
James Davis, PharmD, BCOP retweeted
Want to know why those other countries have lower brand drugs prices than us ?
They don't have PBMs. We are the ONLY country that uses PBMs.
Insane
James Davis, PharmD, BCOP retweeted
#Myeloma Paper of the Day: US Myeloma Immunotx Consortium teclistamab data: 54% CRS (1.4% G≥3), 11% ICANS (2.2% G≥3), 42% infxns, 53% ≥PR, 45% ≥VGPR, PFS 5.8 mos, 12-mo OS 61%; BCMA CAR w/in 9 mos, hi dz/ferritin, lymphopenia reduce benefit: pubmed.ncbi.nlm.nih.gov/4062…. #mmsm
